TheraRadar
← Back
Data updated: Jul 17, 2026

FALCON PHARMS

Pharma

FALCON PHARMS is a pharmaceutical company focused on Immunology.

1994
Since
2
Drugs
-
Trials
0
New Drugs (2yr)

FALCON PHARMS's Key Drugs

FALCON PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

FALCON PHARMS's Recent FDA Approvals

New NDA/BLA approvals for FALCON PHARMS over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

FALCON PHARMS's Therapeutic Areas

FALCON PHARMS's approved drugs and pipeline span 1 therapeutic area, led by Immunology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 100%
1 drugs

FALCON PHARMS's Top Competitors

FALCON PHARMS's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and AbbVie. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

FALCON PHARMS Pipeline Snapshot

Active clinical trials for FALCON PHARMS across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Immunology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling